Drug Trial Radar · NCT05147220
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,000
Actual
Start
Dec 16, 2021
Primary completion
Jul 21, 2026
Study completion Oct 30, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Conditions
- Relapsing Multiple Sclerosis
Interventions
RemibrutinibDrug
tablet taken orally
TeriflunomideDrug
capsule taken orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized relapse rate (ARR) of confirmed relapses [Core Part]Time frame: From Baseline, up to 30 months
Locations
200 sites in 34 countries. Site status is shown where the registry gives one.
AZ Integrated Neuro and Spine
Phoenix, Arizona
Center for Neurosciences
Tucson, Arizona
The Belinga Clinic
Fort Smith, Arkansas
The Research and Education Inst of Alta Bates Summit Med Grp
Berkeley, California
The Neuron Clinic
Chula Vista, California
Glendale Adventist Medical Center
Glendale, California
Hoag Health System
Newport Beach, California
SC3 Research Pasadena
Pasadena, California
Neuro Center
Pomona, California
Alpine Clinical Research Center
Boulder, Colorado
Christiana Care Health Services
Newark, Delaware
Washington Hospital Center
Washington D.C., District of Columbia
Neurology of Central FL Res Ctr
Altamonte Springs, Florida
Arrow Clinical Trials
Daytona Beach, Florida
Homestead Assoc In Research Inc
Homestead, Florida
Reliant Medical Research
Miami, Florida
Neurological Services of Orlando PA
Orlando, Florida
Orlando Health Clinical Trials
Orlando, Florida
Comprehensive Neurology Clinic
Orlando, Florida
Neurology Associates of Ormond Beach
Ormond Beach, Florida
Neurostudies Inc
Port Charlotte, Florida
Accel Research Sites St Pete-Largo
Seminole, Florida
University Of South Florida
Tampa, Florida
Conquest Research
Winter Park, Florida
Rush University Medical Center
Chicago, Illinois
IU Health Inc
Fort Wayne, Indiana
College Park Family Care Center
Overland Park, Kansas
Norton Neurology MS Services
Louisville, Kentucky
American Oncology Partners PA Center for Cancer and Blood Disorders
Bethesda, Maryland
Neurology Center of New England PC
Foxborough, Massachusetts
Wayne State University Multiple Sclerosis Clinic
Detroit, Michigan
The MS Center for Innovation in Care
St Louis, Missouri
SCL Health
Billings, Montana
Jersey Shore University Medical Ctr
Neptune City, New Jersey
Neurological Associates of Long Island PC
Lake Success, New York
NYU Langone Med Center CV Research
New York, New York
The Neurological Institute PA
Charlotte, North Carolina
Velocity Clinical Research
Raleigh, North Carolina
Columbus Neuroscience
Westerville, Ohio
Multiple Sclerosis Center of Excellence of OMRF
Oklahoma City, Oklahoma
Showing 40 of 200 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.